Table 3 Clinical-pathological parameters of patients in the screening and validation cohort
microarray screening cohort | PCR validation cohort | tissue microarray cohort | ||
|---|---|---|---|---|
n = 15 (%) | cancer n = 52 (%) | normal n = 51 (%) | n = 134 (%) | |
Sex | ||||
male | 10 (66.6) | 35 (67.3) | 35 (68.6) | 85 (63.4) |
female | 5 (33.3) | 17 (32.7) | 16 (31.4) | 49 (36.6) |
Age | ||||
mean | 61.2 | 62.5 | 62.0 | 62.3 |
min-max | 43-86 | 36-86 | 36-86 | 33-85 |
Pathological stage | ||||
pT1 | 4 (26.7) | 29 (55.8) | n.a. | 55 (41.0) |
pT2 | 2 (13.3) | 5 (9.6) | n.a. | 30 (22.4) |
pT3 | 9 (60.0) | 17 (32.7) | n.a. | 47 (35.1) |
pT4 | 0 (0) | 1 (1.9) | n.a. | 2 (1.5) |
lymph node metastasis | 0 (0) | 2 (3.8) | n.a. | 7 (5.2) |
distant metastasis | 1 (6.7) | 7 (13.5) | n.a. | 17 (12.7) |
Fuhrman Grading | ||||
grade 1 | 2 (13.3) | 4 (7.7) | n.a. | 40 (29.9) |
grade 2 | 11 (73.3) | 40(76.9) | n.a. | 91 (67.9) |
grade 3 | 2 (13.3) | 7 (13.5 %) | n.a. | 3 (2.2) |
grade 4 | 0 (0) | 1 (1.9) | n.a. | 0 |